To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
The source supplies the latest action, but no lifecycle stage.
Latest action (20 Jul 2026): Referred to the House Committee on Energy and Commerce.
What this bill does
This bill, H.R. 9774, proposes to amend the Federal Food, Drug, and Cosmetic Act to create a system for expedited approval of certain nonprescription drugs. Specifically, it would allow the Secretary of Health and Human Services to designate a nonprescription drug as "priority" if it meets certain criteria, such as being intended for a novel indication with potential public health benefits, being a new molecular entity, or containing an active ingredient not previously available over-the-counter. Drugs subject to risk evaluation and mitigation strategies or controlled substances would not be eligible.
If a drug is designated as a priority nonprescription drug, the Secretary would be required to take steps to facilitate its development and expedite its review. This could include increased communication with the drug sponsor, involvement of senior staff, and assignment of a dedicated project lead. The bill also mandates the creation of a list of conditions where a nonprescription drug could provide significant public health benefit and requires a report to Congress on the implementation of these provisions. The authority granted by this section would expire on September 30, 2032.
This bill was introduced in the House of Representatives by Representative Robert Latta and referred to the Committee on Energy and Commerce. As of its introduction date, it has not moved beyond this initial stage in the legislative process.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
20 Jul 2026
Referred to the House Committee on Energy and Commerce.
Common questions
- What does H.R. 9774 do?
- This bill, H.R. 9774, proposes to amend the Federal Food, Drug, and Cosmetic Act to create a system for expedited approval of certain nonprescription drugs. Specifically, it would allow the Secretary of Health and Human Services to designate a nonprescription drug as "priority" if it meets certain criteria, such as being intended for a novel indication with potential public health benefits, being a new molecular entity, or containing an active ingredient not previously available over-the-counter. Drugs subject to risk evaluation and mitigation strategies or controlled substances would not be eligible. If a drug is designated as a priority nonprescription drug, the Secretary would be required to take steps to facilitate its development and expedite its review. This could include increased communication with the drug sponsor, involvement of senior staff, and assignment of a dedicated project lead. The bill also mandates the creation of a list of conditions where a nonprescription drug could provide significant public health benefit and requires a report to Congress on the implementation of these provisions. The authority granted by this section would expire on September 30, 2032. This bill was introduced in the House of Representatives by Representative Robert Latta and referred to the Committee on Energy and Commerce. As of its introduction date, it has not moved beyond this initial stage in the legislative process.
- Has H.R. 9774 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 9774. Check the latest action and official source below.
- Who sponsored H.R. 9774?
- H.R. 9774 was sponsored by Rep. Latta, Robert E. [R-OH-5] (R-OH), with 1 cosponsor.
- What's the latest action on H.R. 9774?
- Referred to the House Committee on Energy and Commerce. (20 Jul 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
More bills from Rep. Latta, Robert E. [R-OH-5]
BEDROCK Act
Collaboration on Adversarial Threats and Security Risks Act
STOP Nitazenes Act
Nuclear REFUEL (Recycling Efficient Fuels Utilizing Expedited Licensing) Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.